Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thymoma 1 Thymic epithelial tumor 1

Interventions

Cyclophosphamide 7 pembrolizumab 6 Radiotherapy 6 Cisplatin 6 Sunitinib 5 Carboplatin 5 Paclitaxel 4 Thymectomy 3 130-nm albumin-bound paclitaxel 3 selinexor 2 lenvatinib 2 fludarabine 2 Taxes 2 Robotic Surgical Procedures 2 Ramucirumab 2 Prednisone 2 Pemetrexed 2 Octreotide 2 Nivolumab 2 N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 2 Methylprednisolone 2 Imatinib Mesylate 2 Etoposide 2 Erlotinib Hydrochloride 2 Drug Therapy 2 Doxorubicin 2 Chemoradiotherapy 2 Celecoxib 2 zimberelimab 1 vorolanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Thymoma × AP 1903 reagent × Thoracic × Clear all

NCT07598955 2026-05-20

SELECT-NK-THYM

Beijing Biotech

Phase 1/2 Recruiting

Thymic epithelial tumor, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡